Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Dasatinib is safe and active in pediatric CML (Gore et al., 2018)

Until recently, for pediatric patients with chronic myeloid leukemia (CML), imatinib was the only approved BCR-ABL1 targeted tyrosine kinase inhibitor (TKI). However, approximately 30% of patients discontinue imatinib as a result of resistance or intolerance.

The phase II international study in newly diagnosed (n=84) and in imatinib resistent or intolerant (n=29) CML patients presented here, showed that patients receiving dasatinib achieve rapid and deep responses, as summarized in the table below.



3 months

6 months

12 months

24 months

Imatinib R/I cohort


55% MCyR

41% CCyR


66% CCyR

90% MCyR

76% CcyR

41% MMR

90% MCyR

83% CcyR

55% MMR

Newly diagnosed cohort


35% CCyR

64% CCyR

92% CcyR

52% MMR

94% CcyR

70% MMR

95% PFS

R/I=resistant/intolerant; McyR=major cytogenetic response; CcyR=complete cytogenetic response; MMR=major molecular response.